PVI
SUPN icon

Pura Vida Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Pura Vida Investments’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,000
Closed -$2.75M – 120
2019
Q3 		$2.75M Buy
+100,000
New +$2.96M 0.47% 57
2017
Q2 		– Sell
-105,000
Closed -$3.29M – 88
2017
Q1 		$3.29M Buy
+105,000
New +$2.81M 0.97% 46

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pura Vida Investments's SUPN Position: Q3 2017 in Review

Pura Vida Investments sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 80,000 shares — an estimated $3.45M sold.

Pura Vida Investments first reported a position in SUPN in Q4 2016 and held it in 3 quarters. The position peaked at $5.4M in Q1 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Pura Vida Investments reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Pura Vida Investments sold 80,000 Supernus Pharmaceuticals shares in Q3 2017, an estimated $3.45M.
  • Pura Vida Investments first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Pura Vida Investments's Supernus Pharmaceuticals position peaked at $5.4M in Q1 2017.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.